In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注《European journal of nuclear medicine and molecular imaging》(影响因子8.6)上发表的重要综述"Advances in PET imaging of oxidative stress: tracer innovation, mechanistic insight, and translational potential."。这项研究探讨了氧化应激作为多种疾病（包括神经退行性疾病、癌症、心血管损伤和炎症）的关键驱动因素。文章重点介绍了新型PET示踪剂如何实现对活性氧和氮物种的选择性成像，为无创监测氧化应激提供了革命性工具。这一突破性技术有望彻底改变我们对氧化应激相关疾病的早期诊断、治疗反应监测和个性化医疗的实践，为临床医生提供前所未有的疾病可视化能力。

The FDA has recently stepped up its enforcement of pharmaceutical advertising rules, issuing 100 cease-and-desist notices and thousands of letters. These notices were largely non-personalized and intended as general guidance, emphasizing that drug advertisements must not create misleading impressions. While such enforcement has always been possible, this renewed effort signals increased regulatory attention, particularly on direct-to-consumer marketing. Historically, FDA enforcement letters h...

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注发表在《Molecular Psychiatry》(IF: 9.6)上的重要研究"The China Brain Multi-omics Atlas Project (CBMAP)"。这一开创性项目构建了首个覆盖千名中国人大脑的多组学图谱，填补了东亚人群在脑研究中的空白。通过整合基因组、表观基因组、转录组、蛋白质组和代谢组数据，CBMAP为理解衰老相关脑表型和神经精神疾病提供了宝贵资源。研究采用的空间转录组学和单核3D染色质结构分析等先进技术，不仅揭示了疾病机制，还增强了全基因组关联研究的实用性。这一突破性成果将显著加速脑障碍的药物发现和精准医疗发展，为全球脑科学研究注入新动力。

This week’s tHEORetically Speaking News Roundup covers the CDC’s ACIP meeting and its implications for U.S. vaccine policy, GHO Capital’s acquisition of AI-powered R&D platform Scientist.com, and GSK’s $30 billion investment in U.S. drug manufacturing. We also explore Eli Lilly’s promising pediatric trial results for Mounjaro in type 2 diabetes and several upcoming FDA decisions poised to reshape the pharmaceutical landscape. Tune in for this concise recap of these pivotal industry upda...

Friedemann Zenke’s 2019 paper, and its related coding tutorial SpyTorch, made it possible to apply modern machine learning to spiking neural networks. The innovation reinvigorated the field.

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注发表在《Advanced drug delivery reviews》(影响因子：15.2)上的重要研究"Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies"。这项研究揭示了胰腺导管腺癌的复杂异质性，展示了特定基因改变如何塑造独特的肿瘤微环境，影响成纤维细胞编程和免疫细胞组成。作者提出了多细胞亚型分类和空间组织对患者预后的重要影响，为精准医疗提供了新视角。研究不仅阐明了肿瘤-基质网络的复杂相互作用，还探讨了针对肿瘤和基质双重弱点的创新治疗策略，为这一难治性癌症的个体化治疗开辟了新途径。

In this episode, we explore why conforming to people's expectations has never saved anyone's soul. [0.01] Introduction[0.43] Chelle reads the storybook[1.16] Evie guides listeners through the too Shake It Off [2.35] Outro This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit michellemcquaid.substack.com

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In this episode of STBYM’s The Monstrefact, Robert discusses the Neuralian Mugatos of Star Trek… See omnystudio.com/listener for privacy information.

科研喵使用AI读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注发表在《Trends in pharmacological sciences》(IF: 13.9)上的综述《The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics》。这项研究揭示了B7-H3作为免疫检查点配体和肿瘤相关抗原的多重功能，不仅参与二聚化、糖基化和细胞代谢调控，还发现其作为肥胖调节剂的新作用。临床试验证明，针对B7-H3的抗体药物偶联物和CAR免疫细胞在不同癌症中安全有效。研究还介绍了多种新型靶向疗法，包括TOP CAR细胞、双特异性ADCs和CAR-NK细胞，为癌症免疫治疗开辟了新途径。

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。今天我们要介绍发表在《Trends in pharmacological sciences》(IF:13.9)上的重要综述"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics"。这项研究揭示了B7-H3作为免疫检查点配体和肿瘤相关抗原的多重功能，不仅参与肿瘤微环境调控，还发现其与肥胖相关的新作用。更令人振奋的是，针对B7-H3的抗体药物偶联物和CAR细胞临床试验已在多种癌症中显示出安全性和有效性。此外，研究者还介绍了TOP CAR细胞、双特异性ADCs等创新疗法，为癌症免疫治疗开辟了新途径。这项研究为理解B7-H3的生物学功能和开发靶向疗法提供了重要见解。

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。今天我们要介绍一篇发表在《Trends in pharmacological sciences》(影响因子13.9)上的重要综述——《The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics》。这项研究揭示了B7-H3这一免疫检查点配体在癌症和肥胖中的双重作用，不仅是一种肿瘤相关抗原，还新发现它能调节肥胖。更令人兴奋的是，靶向B7-H3的抗体药物偶联物和CAR细胞疗法已在临床试验中展现出良好的安全性和有效性。这些突破性发现为癌症免疫治疗开辟了新途径，可能改变未来多种癌症的治疗格局。

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

Vamos hablar sobre los capitulos 10,11 y 12 del libro